Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00180
|
|||||
| Drug Name |
Levetiracetam
|
|||||
| Synonyms |
(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Etiracetam levo-isomer; Etiracetam, S-isomer; Keppra; Keppra (TN); Keppra XR; Keppra, Keppra XR),Levetiracetam; L-059; Levetiracetam [INN]; Levetiracetamum [INN-Latin]; Levetiractam; Leviteracetam; SIB-S1; Torleva; UCB-22059; UCB-L 059; UCB-L059; Ucb L060
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Epilepsy [ICD11: 8A6Z] | Approved | [1] | |||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H14N2O2
|
|||||
| Canonical SMILES |
CCC(C(=O)N)N1CCCC1=O
|
|||||
| InChI |
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
|
|||||
| InChIKey |
HPHUVLMMVZITSG-LURJTMIESA-N
|
|||||
| CAS Number |
CAS 102767-28-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 170.21 | Topological Polar Surface Area | 63.4 | ||
| Heavy Atom Count | 12 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
-0.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10043
, 103397964
, 11039358
, 113863233
, 11528730
, 118048597
, 118317474
, 12013706
, 121361595
, 124658926
, 124757185
, 124801236
, 125163989
, 125307963
, 126629740
, 126645371
, 126655872
, 128093760
, 131293132
, 134338679
, 135017078
, 135610154
, 135684175
, 135692116
, 135697608
, 136375572
, 15321884
, 15321885
, 26719810
, 39317891
, 46386557
, 48416166
, 49681695
, 49830155
, 50363327
, 56310923
, 56312936
, 56312991
, 56313270
, 57359126
, 68530790
, 7847774
, 7979767
, 90341134
, 91614180
, 92308297
, 92308916
, 92713787
, 93166400
, 99437106
|
|||||
| ChEBI ID |
ChEBI:6437
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Levetiracetam was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.